Sunitinib or Pazopanib: Is There Any Difference Between Tyrosine Kinase Inhibitors in the Pre-Nivolumab Setting in Metastatic Renal Cell Carcinoma?

Introduction Treatment options for metastatic renal cell carcinoma disease have been improved in recent years. However, there is still no optimal treatment sequence or combination for metastatic disease. We aimed to investigate whether patients differed in terms of disease outcomes regarding pre-niv...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cureus
Autors principals: Ucar, Gokhan, Acikgoz, Yusuf, Ergun, Yakup, Bal, Oznur, Yilmaz, Mesut, Karakaya, Serdar, Akdeniz, Nadiye, Kostek, Osman, Aydin Isak, Ozlem, Yazici Sener, Gorkem, Dirikoc, Merve, Aktürk Esen, Selin, Dogan, Mutlu, Uncu, Dogan
Format: Artigo
Idioma:Inglês
Publicat: Cureus 2020
Matèries:
Radiation Oncology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7574822/
https://ncbi.nlm.nih.gov/pubmed/33094066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.10525
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars